课题基金 / 基金详情

Establishment of treatment of Duchenne muscular dystrophy

Establishment of treatment of Duchenne muscular dystrophy
杜氏肌营养不良症治疗方法的建立
批准号:
10557076
负责人:
MATSUO Masafumi
金额:
$8.7万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

MATSUO Masafumi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Duchenne muscular dystrophy (DMD) is a severe muscle wasting disease caused by mutation of the dystrophin gene. DMD patients usually die among the age of 20, but no treatment has been established. We have proposed that out-frame mutation identified in DMD can be corrected to in-frame by inducing exon skipping at the time of splicing. To confirm our proposal, we transfected oligonucleotide which is complementary to splicing enhancer sequence of exon 19 into cultured muscle cells, which was established from DMD case having exon 20 deletion. By this treatment, exon 19 skipping was induced and resulting dystrophin transcript re-gained translational reading frame. Remarkably dystrophin was stained in those transfected cells. This confirms that dystrophin negative cells are able to be converted to dystrophin positive and our proposal is right way to treat DMD.To expand our strategy, we are currently studying splicing enhancer sequence in other exons, dystrophin, splicing, splicing enhancer sequence, exon skipping, treatment
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
Dwi Pramono,ZA, Takeshima,Y, Surono,A, Ishida,T and Matsuo,M.: "A novel cryptic exon in intron 2 of the human dystrophin gene evolved from an intron by acquiring consensus sequence for splicing at different stages of anthropoid evolution"Biochem Biophys R
Dwi Pramono,ZA、Takeshima,Y、Surono,A、Ishida,T 和 Matsuo,M.:“人类肌营养不良蛋白基因内含子 2 中的一个新的神秘外显子是通过在类人猿的不同阶段获得剪接的共有序列而从内含子进化而来的
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Wibawa,T, Takeshima,Y, Mitsuyoshi,H., Surono,A, Nakamura,H and Matsuo,M.: "Complete skipping of exon 66 due to novel mutation of the dystrophin gene was identified in two Japanese families of DMD with severe mental retardation"Brain Dev. (in press). (2000
Wibawa,T、Takeshima,Y、Mitsuyoshi,H.、Surono,A、Nakamura,H 和 Matsuo,M.:“由于抗肌营养不良蛋白基因的新突变,在两个患有严重 DMD 的日本家族中发现了外显子 66 的完全跳跃。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Chen,D,Takeshima,Y,Ishikawa,Y,Ishikawa,Y,Minami,R,Matsuo,M.: "A novel deletion of the dystrophin S-promoter region co-segregating with mental retardation." Neurology. (in press). (1999)
Chen,D,Takeshima,Y,Ishikawa,Y,Ishikawa,Y,Minami,R,Matsuo,M.:“抗肌营养不良蛋白 S 启动子区域的新型缺失与智力障碍共分离。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shiga, N., Matsuo, M., Yokoyama, M and Yokota, Y.: "Study on mutations affecting the muscle promoter/first exon of the dystrophin gene in 92 Japanese dilated cardiomyopathy patients"Am. J. Med. Genet.. 79. 226-227 (1998)
Shiga, N.、Matsuo, M.、Yokoyama, M 和 Yokota, Y.:“影响 92 名日本扩张型心肌病患者肌营养不良蛋白基因肌肉启动子/第一外显子的突变研究”Am。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
20
    Cloning of non-dystrophin transcript from the dystrophin gene
    • 批准号:
      25670480
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2013
    • 负责人:
      MATSUO Masafumi
    • 依托单位:
    Expression of dystrophin via exon skipping with a small chemical
    • 批准号:
      24390267
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.65万
    • 财政年份:
      2012
    • 负责人:
      MATSUO Masafumi
    • 依托单位:
    Dose prostaglandin-mediated inflammation commit to pathology of Duchenne muscular dystrophy?
    • 批准号:
      23659521
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2011
    • 负责人:
      MATSUO Masafumi
    • 依托单位:
    Genes responsible for mental retardation complicating to Duchenne muscular dystrophy
    国内基金
    海外基金
    CircSLTM及其编码多肽SLTM-99aa通过SAFB介导的mRNA剪接重塑在胃癌发生发展中的分子机制及其临床价值研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      胡柯峰
    • 依托单位:
    5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
    • 批准号:
      82372743
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      陈卓佳
    • 依托单位:
    MEK/ERK通路对Bim选择性剪接的调节及其在胃癌细胞对化疗敏感性中作用
    • 批准号:
      81071809
    • 项目类别:
      面上项目
    • 资助金额:
      33.0万元
    • 批准年份:
      2010
    • 负责人:
      张旭东
    • 依托单位:
    c-Abl调控U2AF65介导的mRNA剪接及核质转运机制研究